hypoderm
needl
use
biotherapeut
vaccin
provid
lowcost
rapid
direct
way
deliv
almost
type
molecul
bodi
howev
hypoderm
needl
util
primarili
clinic
home
patient
receiv
special
train
safe
needl
issu
transport
convent
transderm
drug
deliveri
offer
mani
import
advantag
access
safeti
painless
drug
administr
potenti
selfadministr
avoid
enzymat
degrad
gastrointestin
tract
liver
show
low
bioavail
poor
permeabl
drug
physic
barrier
stratum
parenter
controlledreleas
formul
situform
implant
also
attract
altern
preform
implant
microparticl
avoid
use
larg
needl
microsurgeri
rel
low
cost
manufactur
system
stay
solid
state
administr
becom
hydrogel
situ
inject
bodi
howev
key
issu
remain
solv
includ
variabl
implant
shape
structur
avoid
burst
releas
implant
format
toxic
issu
thu
far
practic
recent
peng
et
al
combin
nanoparticl
thermosensit
hydrogel
technolog
appropri
manner
would
promis
system
longer
sustain
control
drug
howev
compar
microneedl
technolog
promis
system
might
lower
patient
complianc
transport
conveni
deadman
et
al
report
recent
situform
drug
depot
eligard
approv
us
food
drug
administr
upon
administr
watermisc
organ
solvent
dissip
surround
tissu
lead
polym
precipit
depot
site
inject
entrap
drug
obviou
disadvantag
fact
organ
solvent
administ
lead
toxic
variabl
shape
size
implant
form
vivo
lead
variabl
rate
drug
microneedl
technolog
first
conceptu
drug
deliveri
mani
decad
ago
overcom
shortag
preserv
advantag
hypoderm
needl
convent
transderm
drugdeliveri
system
extent
also
superior
situform
implant
situform
drug
depot
field
microneedl
needlelik
structur
diamet
size
order
micron
length
structur
use
pierc
upper
layer
skin
enhanc
transderm
drug
deliveri
enabl
transport
host
molecul
deliv
across
skin
passiv
diffus
size
limit
deliveri
macromolecul
microchannel
size
microchannel
micron
maximum
dimens
typic
macromolecul
administ
bodi
thu
microneedl
use
deliv
macromolecul
insulin
growth
hormon
immunobiolog
protein
microneedl
technolog
divid
sever
categori
solid
microneedl
skin
pretreat
increas
skin
permeabl
microneedl
coat
drug
polym
microneedl
encapsul
drug
fulli
partial
dissolv
skin
hollow
microneedl
drug
infus
microneedl
mostli
appli
transderm
deliveri
drug
vaccin
may
requir
long
exposur
among
dissolv
biodegrad
microneedl
technolog
commonli
seen
compar
bolu
deliveri
sustain
deliveri
drug
vaccin
complic
trend
microneedl
technolog
thu
articl
review
bodi
work
stratum
corneum
thick
indispens
barrier
viabl
epidermi
locat
stratum
corneum
thick
epidermi
lie
dermi
thick
contain
nerv
blood
vessel
nociceptor
lymph
vessel
hair
follicl
sweat
gland
figur
epiderm
epitheli
layer
cover
carri
superfici
dermi
superfici
lamina
superfici
plexu
case
skin
model
plexu
intraderm
plexu
lymphat
vessel
layer
deep
dermal
layer
deep
lamina
deep
plexu
carri
case
skin
subderm
plexu
layer
lymphat
vessel
collagen
content
layer
much
greater
superfici
long
recogn
highli
immun
reactiv
tissu
contain
abund
antigenpres
cell
immunocompet
cell
especi
within
epiderm
dermal
skin
skin
microanatomi
larg
determin
geometri
microneedl
yana
et
al
prove
microneedl
array
longer
needl
effect
creat
pathway
across
skin
enhanc
drug
flux
microneedl
array
lower
needl
densiti
effect
enhanc
drug
flux
microneedl
suffici
length
noh
et
measur
skin
irrit
use
microneedl
depth
conclud
littl
differ
decreas
red
microneedl
applic
base
applic
time
red
gener
maintain
minut
rapidli
decreas
minut
hour
gomaa
et
found
microneedl
appli
dermal
side
skin
transepiderm
waterloss
measur
remain
baselin
level
explain
fact
typic
needl
length
actual
penetr
gomaa
et
also
found
increas
microneedl
densiti
introduc
complex
effect
firstli
skin
channel
may
creat
inhibit
longterm
tissu
contractionmedi
partial
recoveri
barrier
howev
also
evid
high
microneedl
densiti
individu
needl
may
longer
effect
breach
barrier
due
bed
nail
effect
leav
array
embed
skin
seem
diminish
magnitud
initi
postinsert
drop
barrier
function
furthermor
lee
et
conclud
pyramid
microneedl
stronger
conic
one
probabl
due
larger
crosssect
area
base
widthdiamet
dissolv
microneedl
mostli
use
differ
kind
sugar
matrix
figur
usual
releas
drug
vaccin
quickli
eg
ito
et
report
insulin
releas
microneedl
quickli
almost
formul
insulin
releas
within
hour
dextrin
use
matrix
nevertheless
sustain
releas
drug
vaccin
also
requir
circumst
lee
et
prepar
microneedl
model
drug
encapsul
within
microneedl
tip
back
layer
serv
controlledreleas
reservoir
deliv
molecul
combin
swell
back
interstiti
fluid
drawn
skin
molecul
diffus
skin
via
channel
form
dissolv
microneedl
reveal
sulforhodamin
releas
carboxymethyl
cellulos
microneedl
patch
exhibit
initi
lag
time
hour
follow
steadi
releas
approxim
day
similar
behavior
seen
microneedl
patch
made
amylopectin
slower
kinet
case
lag
time
longer
releas
took
place
day
polymer
dissolv
microneedl
design
donnelli
et
al
produc
gantrez
deliv
encapsul
theophyllin
porcin
skin
within
kumar
et
character
use
maltos
microneedl
micropor
fullthick
pigear
skin
evalu
drug
deliveri
model
small
calcein
larg
human
growth
hormon
molecul
found
modul
transderm
deliveri
small
well
larg
molecul
possibl
upon
micropor
skin
combin
iontophoresi
itp
modul
itp
protocol
result
peak
flux
applic
current
gradual
decreas
termin
current
current
densiti
time
could
use
appropri
program
desir
drugdeliveri
profil
garland
et
studi
potenti
itp
combin
polymer
microneedl
devic
remain
contact
skin
cours
drug
deliveri
procedur
first
time
furthermor
shown
applic
electr
current
enabl
permeat
macromolecul
entir
microneedlearray
matrix
contain
within
microneedl
alon
thu
applic
electr
current
significantli
increas
extent
macromolecular
deliveri
poli
methyl
vinyl
ether
maleic
anhydrid
microneedl
array
also
promis
sustain
deliveri
drug
vaccin
wu
et
report
similar
find
wherein
transderm
permeat
highmolecularweight
compound
microneedleinduc
channel
could
increas
combin
itp
ito
et
al
report
sustainedreleas
selfdissolv
micropil
sdmp
porou
silicon
dioxid
porou
calcium
silic
use
nanopor
microparticl
adsorb
insulin
microparticleadsorb
insulin
mold
sdmp
use
chondroitin
sulfat
base
conclud
longact
sdmp
prepar
would
possibl
mean
porou
silic
adsorbentheld
biodegrad
microneedl
mostli
use
differ
kind
biodegrad
polym
includ
polylact
acid
chitosan
polyglycol
acid
poli
lactidecoglycolid
plga
form
matrix
degrad
skin
applic
wherebi
releas
incorpor
drug
sustain
month
choos
proper
polym
previou
studi
demonstr
possibl
biodegrad
microneedl
patientfriendli
substitut
convent
sustaineddeliveri
howev
microneedl
must
insert
remain
skin
sever
day
util
degrad
properti
biodegrad
polym
effect
kim
et
demonstr
microneedl
separ
skin
mediat
hydrogel
swell
respons
contact
bodi
fluid
needl
insert
skin
hydrogel
particl
absorb
water
quickli
result
crack
microneedl
due
differ
volum
expans
needlematrix
polym
hydrogel
particl
swollen
particl
caus
microneedl
total
break
leav
microneedl
tip
porcin
cadav
skin
vitro
hairless
mous
skin
vivo
figur
chu
et
introduc
separ
arrowhead
microneedl
featur
microns
sharp
tip
mount
blunt
shaft
upon
insert
skin
sharptip
polym
arrowhead
encapsul
drug
separ
metal
shaft
remain
embed
skin
subsequ
dissolut
drug
releas
blunt
metal
shaft
discard
due
rapid
separ
arrowhead
tip
shaft
within
second
administr
use
arrowhead
microneedl
carri
rapidli
drugreleas
kinet
independ
control
base
separ
arrowhead
formul
figur
park
et
develop
array
microneedl
fabric
plga
use
moldbas
techniqu
encapsul
model
drug
calcein
bovin
serum
albumin
either
singl
encapsul
within
needl
matrix
doubl
encapsul
first
encapsul
drug
within
carboxymethyl
cellulos
polyllactid
microparticl
encapsul
drugload
microparticl
within
needl
vitro
releas
calcein
bovin
serum
albumin
three
differ
encapsul
formul
measur
time
shown
control
encapsul
method
achiev
releas
kinet
rang
hour
month
tsiori
et
report
fabric
method
produc
silk
biopolym
microstructur
high
aspect
ratio
requir
manufactur
microneedl
system
room
temperatur
aqueousbas
micromold
allow
bulk
load
microneedl
structur
temperaturesensit
drug
peptid
antibiot
vaccin
temperaturelabil
therapeut
control
releas
model
drug
achiev
adjust
postprocess
condit
microneedl
structur
mainli
control
silk
protein
secondari
structur
ausiello
et
releas
method
extend
control
deliveri
parathyroid
hormon
patient
need
involv
implant
medic
devic
patient
medic
devic
compris
substrat
plural
reservoir
substrat
releas
system
contain
reservoir
wherein
releas
system
compris
parathyroid
hormon
control
releas
pharmaceut
effect
amount
parathyroid
hormon
reservoir
microneedl
deliveri
nucleic
acid
particular
plasmid
dna
pdna
skin
repres
potenti
new
approach
clinic
manag
genet
skin
diseas
cutan
cancer
intracutan
genet
immun
dna
vaccin
mani
potenti
benefit
fail
gener
robust
immun
respons
demuth
et
report
approach
rapid
implant
vaccineload
polym
film
carri
dna
immunestimulatori
rna
biodegrad
polyc
use
microneedl
coat
releas
polyelectrolyt
multilay
promot
local
transfect
control
persist
dna
adjuv
skin
day
week
kinet
determin
film
composit
multilay
tattoo
dna
vaccin
induc
immun
respons
model
hiv
antigen
compar
electropor
mice
enhanc
memori
tcell
gener
elicit
higher
gene
express
nonhuman
primat
skin
intraderm
dna
inject
indic
potenti
strategi
enhanc
dna
vaccin
figur
marc
pearton
et
prove
pdnacoat
microneedl
facilit
reportergen
express
viabl
human
skin
whilst
effici
gene
express
coat
microneedl
depend
upon
suitabl
dna
load
effici
reproduc
skin
punctur
rapid
situ
dissolut
plasmid
site
deliveri
fabric
microneedl
usual
follow
step
mold
prepar
microneedl
matrix
cast
remov
concret
method
determin
desir
properti
microneedl
howev
harsh
fabric
method
ie
use
high
temperatur
organ
solvent
may
damag
temperaturesensit
drug
particularli
peptid
protein
review
mainli
focus
mild
fabric
method
vacuum
centrifug
often
appli
cast
microneedl
matrix
mold
whilst
polydimethylsiloxan
micromold
creat
precis
morpholog
fidel
master
microneedl
structur
sugar
solut
complet
fill
micromold
invagin
due
high
surfac
tension
solut
martin
et
reveal
simpl
novel
lowtemperatur
vacuumdeposit
micromold
methodolog
biodegrad
sugarglass
microneedl
fabric
origin
vacuumoven
method
vacuum
pressur
could
appli
sugar
solut
place
mold
surfac
subsequ
droplet
sugar
solut
appli
air
entrap
within
micromold
invagin
optim
method
develop
wherebi
vacuum
produc
within
enclos
chamber
sugar
solut
appli
mold
surfac
demuth
et
develop
microneedlefabr
method
featur
drugload
plga
microparticl
solid
plga
tip
plga
microparticl
appli
surfac
mold
aqueou
suspens
compact
mold
caviti
centrifug
excess
microparticl
remov
microparticleload
mold
allow
dri
concentr
aqueou
solut
poli
acryl
acid
ad
mold
surfac
infiltr
pack
plga
particl
bed
via
centrifug
dri
vacuum
solid
plgapoli
acryl
acid
microparticl
matrix
obtain
microparticleload
polydimethylsiloxan
mold
dri
incub
vacuum
fuse
embed
plga
particl
solidifi
plga
tip
obtain
demuth
et
demonstr
new
approach
dna
vaccin
via
multilay
tattoo
use
microneedl
employ
phrespons
releas
layer
implant
biodegrad
vaccineload
polym
film
rapidli
skin
mefti
et
al
releas
patent
concern
administr
drug
microneedl
specif
concern
microneedl
compris
part
dissolv
hydrolysi
penetr
also
conclud
enhanc
method
itp
well
differ
drug
carrier
eg
microand
nanoparticl
appli
fabric
microneedl
effect
circumv
skin
barrier
offer
rout
potenti
altern
oral
parenter
deliveri
rel
larg
dose
administ
due
bulk
load
dissolv
biodegrad
system
howev
still
sever
problem
remain
solv
exampl
barrier
function
skin
chang
one
site
anoth
person
person
person
import
ensur
patient
obtain
requir
dose
microneedl
administr
sinc
differ
individu
skin
penetr
depth
microneedl
relat
stress
upon
skin
thu
applic
may
requir
order
obtain
reproduc
penetr
depth
besid
sustain
releas
drug
vaccin
complic
bolu
releas
kinet
investig
ensur
also
necessari
investig
whether
dissolv
degrad
matric
side
effect
microneedl
use
frequent
although
materi
commonli
seen
excipi
drug
accumul
level
influenc
note
prudenti
reason
addit
microneedlefabr
case
polymermelt
temperatur
vacuum
necessari
process
condit
could
detriment
variou
temperaturesensit
drug
particularli
peptid
protein
polym
microneedl
controlledreleas
deliveri
also
constrain
needl
mechan
properti
main
matrix
plga
carboxymethyl
cellulos
park
et
al
found
microneedl
drug
load
retain
suffici
mechan
strength
needl
load
although
maximum
dose
constrain
applic
controlledreleas
deliveri
mg
number
candid
drug
market
like
approv
dna
vaccin
intens
studi
potenti
advantag
eas
goodmanufacturingpractic
product
lack
antivector
immun
capabl
promot
cellular
humor
immun
sinc
genet
engin
dna
deliv
vaccin
form
elicit
immun
respons
much
progress
understand
basic
biolog
larg
amount
data
gener
preclin
model
sustain
cellular
respons
consist
antibodi
respons
observ
microneedl
applic
promis
promot
local
transfect
control
persist
dna
adjuv
skin
day
week
function
optim
strategi
safe
reproduc
painfre
dna
vaccin
therapeut
protein
preserv
protein
structur
manufactur
storag
use
consid
even
import
vaccin
unwant
immunogen
lead
total
loss
therapeut
effect
protein
neutral
antibodi
may
even
lead
deplet
endogen
protein
break
immun
toler
selfantigen
dissolv
microneedl
futur
studi
partial
focu
upon
incorpor
bioactivityenhanc
method
includ
itp
compon
polymer
microneedl
devic
investig
potenti
effici
electr
control
pulsatil
deliveri
macromolecul
drugload
dissolv
polymer
microneedl
altogeth
dissolv
biodegrad
microneedl
technolog
bright
futur
transderm
sustain
deliveri
drug
vaccin
requir
